Aktie A3D1K3 BIONXT SOLUTIONS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen BioNxt Solutions Inc.

Aktien

A3D1K3

CA0909741062

BNXT

Verzögert Canadian Securities Exchange
Andere Börsenplätze
 15:58:35 10.05.2024 		% 5 Tage % 1. Jan.
0.41 CAD +2.50% Intraday Chart für BioNxt Solutions Inc. -3.53% -15.46%
26.04. BioNxt Solutions Inc. gibt Update zu ODF Cladribin bekannt CI
22.04. BioNxt Solutions Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BioNxt Solutions Inc. Announces ODF Cladribine Update
BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding
BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
BioNxt Solutions Provides Update on Commercialization of ODF Cladribine Product for Multiple Sclerosis
BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps
BioNxt Solutions Reported Results From ODF Cladribine PK Study
BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study
BioNxt Solutions Reports Completion of ODF Cladribine PK Study
BioNxt Solutions Finalizes Agreement
BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study
BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding
BioNxt Solutions Completed Cladribine ODF Toxicity Study and Financing
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
BioNxt Solutions Inc. announced that it expects to receive CAD 2.4 million in funding
BioNxt Solutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program
BioNxt Solutions Inc. announced that it has received CAD 2.00075 million in funding
BioNxt Solutions Inc. Announces Change of Directors
BioNxt Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D1K3 Aktie
  4. Nachrichten BioNxt Solutions Inc.
  5. Andere Sprachen